Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.61 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.51 |
| ▸ | PARP3 | Q9Y6F1 | 5/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016308 | 1.00 | PARP1 (0.61) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL1421856 | 0.92 | PARP1 (0.61) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL23854758 | 0.92 | PARP1 (0.61) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL21743067 | 0.91 | PARP1 (0.50) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL1422522 | 0.91 | PARP1 (0.50) | PARP1PARP2PARP3TNKSCHRM2 | |
| Lithium Ion SCHEMBL29393507 | 0.91 | PARP1 (0.50) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL15777226 | 0.90 | PARP1 (0.49) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL15777224 | 0.90 | PARP1 (0.49) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL15786487 | 0.88 | PARP1 (0.47) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL17181683 | 0.88 | PARP1 (0.47) | PARP1PARP2PARP3TNKSCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271233-A | Nilaparil manufacturing method | 特沙诺有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118084772-A | Nilapatinib intermediate, preparation method and method for preparing Nilapatinib by using same | 重庆博腾制药科技股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3668857-B1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-11629137-B2 | Methods of manufacturing of niraparib | TESARO, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| CN-106008460-B | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | 默沙东公司 | 2022-08-12 | — | — | CN | disclosed |
| EP-3615513-B1 | METHODS OF MANUFACTURING OF NIRAPARIB | TESARO INC (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11161834-B2 | Methods of manufacturing of niraparib | TESARO, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-10927095-B2 | Processes for the preparation of Niraparib and intermediates thereof | TEVA PHARMACEUTICALS INTERNATIONAL GMBH | 2021-02-23 | — | — | US | disclosed |
| US-20200190056-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2020-06-18 | — | — | US | disclosed |
| US-20200055837-A1 | METHODS OF MANUFACTURING OF NIRAPARIB | TESARO, INC. | 2020-02-20 | — | — | US | disclosed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | disclosed |
| EP-2240466-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME (GB) | 2015-07-29 | — | — | EP | disclosed |
| EP-2805945-A1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD Italia S.r.l. (IT) | 2014-11-26 | — | — | EP | disclosed |
| CN-101578279-B | Amide substituted indazoles as poly (ADP ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO | 2013-07-17 | — | — | CN | disclosed |
| US-8436185-B2 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8071623-B2 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA | 2011-12-06 | — | — | US | disclosed |
| EP-2336120-A1 | Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) | 2011-06-22 | — | — | EP | disclosed |
| EP-2109608-B1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-03-23 | — | — | EP | disclosed |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-20200055837-A1 | METHODS OF MANUFACTURING OF NIRAPARIB | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885PARP3 3/4885 |
| US-10927095-B2 | Processes for the preparation of Niraparib and intermediates thereof | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP3 3/4885 |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | PARP1, PARP12, PARP15 | PARP1 1/4885PARP2 6/4885PARP3 7/4885 |
| US-11161834-B2 | Methods of manufacturing of niraparib | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885PARP3 3/4885 |
| US-11629137-B2 | Methods of manufacturing of niraparib | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885PARP3 3/4885 |
| US-20200190056-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.